Want to join the conversation?
In 4Q15, $VRTX initiated Phase 2 clinical trial to evaluate VX-150, inhibitor of sodium channel known as NaV 1.8 involved in pain sensation, which is expected to enroll about 100 patients who have symptomatic osteoarthritis of knee. $VRTX expects to begin clinical development of VX-241, inhibitor of sodium channel known as NaV 1.7, in 1H16.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!